Study of the Safety and Efficacy of Ruxolitinib Cream for Non-Sclerotic Chronic Cutaneous Graft-Versus-Host Disease

NCT03954236 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Non-sclerotic Cutaneous Chronic Graft-versus-host Disease

Interventions

DRUG: topical ruxolitinib 1.5% cream
OTHER: Topical vehicle/moisturizer cream

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]
[object Object]